Skip to Content

11.1 Anaphylaxis Cases/Million Doses of Pfizer-BioNTech COVID-19 Vaccine Reported

THURSDAY, Jan. 7, 2021 -- As of Dec. 23, 2020, researchers determined there were 21 cases of anaphylaxis (11.1 per million doses administered) after receipt of the first dose of the Pfizer-BioNTech COVID-19 vaccine in the United States, according to research published in the Jan. 6 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Researchers from the CDC COVID-19 Response Team and the U.S. Food and Drug Administration examined allergic reactions, including anaphylaxis, after receipt of the first dose of the Pfizer-BioNTech COVID-19 vaccine from Dec. 14 to 23, 2020.

The researchers note that as of Dec. 23, 2020, 1,893,360 first doses of the Pfizer-BioNTech COVID-19 vaccine had been administered in the United States, and there were reports of 4,393 (0.2 percent) adverse events submitted to the Vaccine Adverse Event Reporting System (VAERS). One hundred seventy-five of these events were identified as possible cases of severe allergic reaction, including anaphylaxis. Overall, 21 cases were determined to be anaphylaxis (11.1 per million doses administered), including 17 in individuals with a documented history of allergies or allergic reactions, of whom seven had a history of anaphylaxis. From vaccine receipt to symptom onset, there was a median interval of 13 minutes. All 20 persons with follow-up information had recovered or been discharged home.

"Health care providers can play an important role in vaccine safety by being vigilant in recognizing and reporting adverse events after immunization to VAERS," the authors write.

Abstract/Full Text

© 2021 HealthDay. All rights reserved.

Posted: January 2021

Read this next

Mortality, Preeclampsia Up for Women With COVID-19 Giving Birth

WEDNESDAY, Jan. 20, 2021 -- Among U.S. women hospitalized for childbirth, the rates of death and certain adverse events are increased among those diagnosed with COVID-19,...

New York City May Run Out of COVID-19 Vaccines

WEDNESDAY, Jan. 20, 2021 -- New York City's COVID-19 vaccination rate has outpaced its supply of vaccine doses, and the city could run out of doses in the next few days, Mayor...

Men More Likely to Test Positive for SARS-CoV-2, Die From COVID-19

WEDNESDAY, Jan. 20, 2021 -- Men are more likely to test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to have complications of COVID-19, according...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.